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Background: Dysmenorrhea affects most reproductive-age women. Common dysmenorrhea 
treatments vary in their effectiveness across individuals. Little is known about factors associated 
with perceived treatment ineffectiveness. The objectives of this study were to describe the 
perceived ineffectiveness of common pharmacological treatments for dysmenorrhea and 
investigate factors associated with perceived treatment ineffectiveness.  
Methods: In this cross-sectional study, 678 women with dysmenorrhea (aged 14 to 42) 
provided data on perceived treatment ineffectiveness, dysmenorrhea symptom-based 
phenotypes, demographics, clinical factors, and psycho-behavioral characteristics. We used 
Fisher’s exact tests to compare treatment ineffectiveness across three symptom-based 
phenotypes. We used logistic regressions to explore associations of phenotype, demographic, 
clinical, and psycho-behavioral correlates of perceived treatment ineffectiveness.  
Results: Percentages perceiving treatments as ineffective were: 29.3% to 35.6% nonsteroidal 
anti-inflammatory drugs, 49.9% acetaminophen, 39.3% combined oral contraceptive pills 
(OCPs). Factors associated with perceived ineffectiveness varied across treatments and 
included symptom-based phenotypes, clinical, and psycho-behavioral factors. For ibuprofen and 
acetaminophen, women with severe (vs. mild) pain phenotype and higher number of chronic 
pain conditions were more likely to perceive the treatments as ineffective. For OCPs, women 
with severe pain (vs. mild) phenotype, comorbid gynecological condition, less anxiety, and 
worse depressive symptoms were more likely to perceive the treatment as ineffective.  
Conclusion: A significant percentage of women reported ineffectiveness of dysmenorrhea 
treatments. Phenotypes, clinical, and psycho-behavioral factors were associated with treatment 
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ineffectiveness. Future research should test if symptom-based phenotypes are associated with 
treatment effectiveness in clinical trials and investigate other factors that affect dysmenorrhea 
treatment effectiveness so treatments can be tailored to individuals.  
Keywords: Dysmenorrhea, Pain, Pelvic Pain, Chronic Pain, Treatment Outcome 
Introduction 
Dysmenorrhea is a chronic pain condition that affects 45% to 95% of reproductive-age 
women.1,2 Dysmenorrhea is characterized by abdominal cramps just before or during 
menstruation. Women with dysmenorrhea also may experience low back pain, headaches, and 
gastrointestinal symptoms.3 On a recurrent basis, dysmenorrhea negatively affects women’s 
physical activities, sleep, and quality of life.1 In the European Union, dysmenorrhea results in 3.6 
million quality-adjusted life years lost annually, which is comparable to losses from chronic 
diseases such as type 1 diabetes, asthma, or chronic migraine.4 Dysmenorrhea also can 
interfere with work and school. Among young women globally, 10% to 46% miss one or more 
days of school each month due to dysmenorrhea.2,3,5 
While the short-term impact of dysmenorrhea on women’s lives is apparent, the long-
term impact of dysmenorrhea is less well-known among researchers and clinicians. 
Dysmenorrhea may increase women’s risk of developing other chronic pain conditions. For 
example, dysmenorrhea is a risk factor for irritable bowel syndrome (IBS)6 and non-cyclic pelvic 
pain.7 In imaging studies, dysmenorrhea has been associated with structural and functional 
changes in the brain, which may make affected women more susceptible to developing other 
chronic pain conditions later in life.8-10 Given the connections between dysmenorrhea and other 
chronic pain conditions, treating dysmenorrhea early and effectively is more important than 
previously recognized.11  
Although evidence-based pharmacological treatments are available for dysmenorrhea, 
their effectiveness varies among women. Cochrane reviews suggest that nonsteroidal anti-
inflammatory drugs (NSAIDs, e.g., ibuprofen, naproxen) and combined oral contraceptives pills 
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(OCPs) are effective dysmenorrhea treatments.12,13 However, on the individual level, NSAIDs 
were ineffective for 18% of women with dysmenorrhea.14,15  
Two gaps in the literature create barriers for effective management of dysmenorrhea. 
First, the effectiveness or ineffectiveness rate for non-NSAIDs dysmenorrhea treatments, 
including OCPs, are rarely reported. Research using qualitative data suggests that some 
women with dysmenorrhea respond well to OCPs, while others find OCPs ineffective for 
menstrual pain.16 Little quantitative data are available regarding the perceived ineffectiveness of 
non-NSAIDs dysmenorrhea treatments.  
Second, little is known about factors that are associated with the perceived 
ineffectiveness of dysmenorrhea pharmacological treatments. In other chronic pain conditions, 
symptom characteristics (e.g., types of symptoms) can affect treatment effectiveness.17 
Symptom-based phenotypes have been identified in dysmenorrhea, including “mild localized 
pain” phenotype (characterized by mild abdominal cramps), “severe localized pain” phenotype 
(characterized by severe abdominal cramps), and “multiple severe symptoms” phenotype 
(characterized by pain at multiple sites and gastrointestinal symptoms).”18 The dysmenorrhea 
symptom-based phenotypes may be related to perceived treatment effectiveness. In addition, 
like other chronic pain conditions,19-23 demographic, clinical, and psycho-behavioral factors may 
explain variations in perceived treatment effectiveness/ineffectiveness in dysmenorrhea.   
Therefore, the purpose of the study was to (1) describe perceived ineffectiveness of 
common pharmacological treatments for dysmenorrhea; (2) test whether perceived treatment 
ineffectiveness differs by dysmenorrhea symptom-based phenotypes; and (3) investigate 
phenotypic, demographic, clinical, and psycho-behavioral correlates of perceived treatment 
ineffectiveness. We hypothesized that perceived treatment ineffectiveness would be associated 
with dysmenorrhea symptom-based phenotypes and other factors. 
Materials and Methods 
Design and Participants 
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This was a cross-sectional descriptive study. Eligibility criteria were (a) female, (b) aged 
14-42, (c) living in the United States, (d) able to read and write English, and (d) self-identified as 
having had dysmenorrhea symptoms in the last 6 months. We recruited participants from online 
survey panels maintained by Qualtrics (Qualtrics, Provo, UT). The panel provider used 
registrants’ demographic data to identify and email invitations to potential participants.  
Procedures 
The university institutional review board approved the study. The survey panel provider 
emailed potential participants about the study opportunity. For those interested in participating, 
they proceeded by clicking the hyperlink to the survey embedded in the e-mail message. 
Further screening of potential participants occurred, directing those eligible to the study 
information page (i.e., the implied consent form). Those who agreed to participate proceeded to 
the survey questionnaires.  
Measurement 
Demographic and Clinical Variables. We collected self-reported demographic and 
clinical data on comorbid chronic pain and gynecological conditions. For comorbid chronic pain 
conditions, participants received instructions to report if they had any of the following chronic 
pain conditions: back pain, irritable bowel syndrome, migraines, non-migraine headaches, 
fibromyalgia, neck pain, pelvic pain outside of the menstrual period, interstitial cystitis, or other 
chronic pain. To determine if participants had comorbid gynecological conditions, we asked 
participants to report whether a healthcare provider had ever diagnosed the participant with 
endometriosis, uterine fibroids, bacterial vaginosis, polycystic ovary syndrome, sexually 
transmitted disease, pelvic inflammatory disease, adenomyosis, and other gynecological 
conditions.  
Perceived Treatment Effectiveness. We collected data on pharmacological treatments 
used by women with dysmenorrhea.24 Participants were asked to select pain medications they 
had ever used to prevent or treat menstrual pain from a checklist of pain medications. The 
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checklist included ibuprofen, naproxen, acetaminophen alone, acetaminophen combined with 
caffeine and antihistamine, acetaminophen combined with antihistamine and diuretic, opioid, 
and other pain medications. We provided examples of common brand names to ensure 
comprehension. For each pain medication they selected, participants received instructions to 
respond to the follow-up question, “How effective was [insert the selected pain medication] to 
manage your menstrual pain?” The five response options were not effective at all, a little 
effective, moderately effective, quite effective, and extremely effective. 
Similarly, participants were asked to select hormonal contraceptives they had ever used 
to prevent or treat menstrual pain from a checklist of hormonal contraceptives. The checklist 
included combined oral contraceptive pill, progestin-only pill (minipill), hormonal intrauterine 
device (IUD), skin patch, medroxyprogesterone acetate injection (shot), implant, and estrogen 
and progestin ring (ring). Examples of common brand names were provided to ensure 
comprehension. For each hormonal contraceptive they selected, participants received a prompt 
to respond to the follow-up question, “How effective was [insert the selected hormonal 
contraceptive] to manage your menstrual pain?” The five response options were not effective at 
all, a little effective, moderately effective, quite effective, and extremely effective. 
For Aims 2 and 3, we dichotomized the five response options into “perceived effective” 
and “perceived ineffective.” Specifically, we combined categories of “extremely effective,” “quite 
effective,” and “moderately effective” into a category of “perceived effective.” We combined 
categories of “a little effective” and “not at all effective” into a category of “perceived ineffective." 
For statistical purposes, dichotomization allows for larger counts in outcome categories and 
intuitive interpretation.  
Symptom-based phenotypes. Participants rated the severity of 14 dysmenorrhea-
related symptoms in their most recent menstrual cycle: abdominal cramps, dull abdominal pain 
or discomfort, low back pain, pain in the upper thighs, headache or migraines, pain when the 
bladder was full, aches all over, bloating, nausea, vomiting, diarrhea (loose stools), constipation 
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(hard stools), more bowel movements than usual, and fewer bowel movements than usual.18,25 
Participants rated the severity of each symptom on a 0 (“not present”) to 10 (“extremely severe”) 
scale. Each severity rating was then grouped into one of four severity categories based on 
established cut points: no symptom (0), mild (1-4), moderate (5-6), and severe (7-10).26,27 Then, 
we conducted a latent class analysis of the symptom severity data. Consistent with previous 
research,18 we identified three symptom-based phenotypes, including “mild localized pain” 
phenotype, “severe localized pain” phenotype, and “multiple severe symptoms” phenotype.18 
Based on probabilities, we grouped individual participants into one of the three dysmenorrhea 
symptom-based phenotypes.  
Psycho-behavioral Variables. We assessed psycho-behavioral symptoms, including 
pain catastrophizing, perceived stress, anxiety, depression, and sleep disturbance.  
Pain catastrophizing is defined as a set of negative thoughts related to pain experiences, 
including rumination, magnification, and helplessness.28 We measured pain catastrophizing with 
the Pain Catastrophizing Scale.29 The 13-item scale measures the extent to which participants 
worry, amplify, and feel helpless about the experience of pain on a 5-point (0 to 4) scale. Total 
scores range from 0 to 52, with higher scores indicating greater pain catastrophizing. The Pain 
Catastrophizing Scale is reliable and valid in clinical and non-clinical samples.29  
Perceived stress was measured by the Perceived Stress Scale,30 a classic, well-
validated stress assessment tool. Participants rate each of the 10 items on a 5-point (0-4) scale; 
the total score ranges from 0-40, with higher scores indicating higher perceived stress. 
Anxiety was measured by the reliable and valid PROMIS Anxiety 8-item Short Form 
(8a).31 The PROMIS Anxiety instrument assesses self-reported fear, anxiety, and tension. 
Participants rated the severity of anxiety symptoms in the past seven days using a 5-point (1-5) 
response scale.  
Depression was measured by the reliable and valid 8-item PROMIS Depression Short 
Form (8b).31 “The PROMIS Depression Short Form assesses self-reported mood, views of self, 
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social cognition, affect, and engagement over the past seven days. Participants rated the 
severity of their depression using a 5-point (1-5) response scale.  
Sleep disturbance was measured by the reliable and valid PROMIS Sleep Disturbance 
8-item Short Form (8b).32,33 Participants rated the severity of sleep disturbance during the past 
seven days using a 5-point (1-5) scale. 
For the three PROMIS scales discussed above, raw scale scores (summed item 
responses range from 8 to 40) were converted to T-scores using a conversion table. A T-score 
of 50 is the average for the United States general population with a standard deviation of 10. A 
higher PROMIS T‐score indicates more of the concept being measured (i.e., severer 
depression, anxiety, and sleep disturbance). More information can be found at 
www.healthmeasures.net.  
Data Analysis  
We used descriptive statistics to summarize participants’ demographic, clinical, and 
psycho-behavioral characteristics. To summarize women’s perceived ineffectiveness of 
common pharmacological dysmenorrhea treatments (Aim 1), we used descriptive statistics, 
specifically counts and frequencies. For a given individual, we counted a treatment as 
ineffective when the participant rated it as “not at all effective” or “a little effective.” 
To test whether perceived treatment ineffectiveness differed by dysmenorrhea symptom-
based phenotypes (Aim 2), we used Fisher’s exact test. Fisher’s exact test was chosen since 
the expected frequencies for less frequently used treatments were smaller than 5. 
We evaluated factors associated with perceived treatment ineffectiveness (Aim 3) for 
three treatments: ibuprofen, acetaminophen, and combined OCP. These treatments were 
selected because at least 25% of the study sample reported using them. The outcome 
reference group was those who perceived a specific treatment as effective. Bivariate models of 
each of the three treatments were fit with symptom-based phenotypes, demographic, clinical, 
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and psycho-behavioral characteristics as explanatory variables. More specifically, independent 
variables were phenotypes, demographic factors (age, race, ethnicity), clinical factors (number 
of comorbid pain conditions, the existence of a comorbid gynecological condition), and psycho-
behavioral factors (pain catastrophizing, perceived stress, anxiety, depression, and sleep 
disturbance). Missingness was assessed to determine if any of the variables considered for 
modeling had large amounts of missing data. Across variables, missing data rates ranged from 
0% to 1% of the cases and were acceptable.  
We built multiple logistic regression models for each treatment by fitting models to each 
possible combination of the 12 explanatory variables. These variables included age, two dummy 
variables for phenotypes, three dummy variables for race, ethnicity, the number of comorbid 
pain conditions, existence of a comorbid gynecological condition, pain catastrophizing, 
perceived stress, anxiety, depression, and sleep disturbance. We selected the model with the 
smallest Akaike’s Information Criterion (AIC) as the best fitting model. This variable selection 
approach has been shown to be consistent, where consistency is defined in terms of model 
selection.34 Correlations were assessed between all the independent variables of interest for the 
model to check for multicollinearity. Also, the variance inflation factors (VIFs) for all three 
models were below three, indicating that multicollinearity between the explanatory variables was 
not a concern.  
The type I error rate was set at a 0.05 level for each test. Statistical analyses were 
performed using the R package.  
Results  
Sample Characteristics  
The mean age of the sample (N=678) was 28.0 years (SD= 7.6; range = 14-42). Most 
were White (67.7%), 13.3% were Black/African American, 7.8% were Asian, and 11.2% were 
other (including American Indian or Alaska Native, Native Hawaiian or Pacific Islander, and 
other). Most participants were non-Hispanic/non-Latino (87.9%).  
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Among participants, more than half (57.7%) had another chronic pain condition, 
including low back pain (31.7%), migraine headaches (28.8%), neck pain (13.9%), non-migraine 
headaches (10.2%), pelvic pain occurring outside of menstrual period (9.7%), and irritable 
bowel syndrome (8.3%). About one-fourth of participants (25.2%) were previously diagnosed 
with another gynecological condition, such as bacterial vaginosis (9.1%), endometriosis (4.9%), 
polycystic ovary syndrome (4.9%), and uterine fibroids (3.1%). The mean score was 18.3 
(SD=12.8) for pain catastrophizing, 22.4 (SD=6.4) for perceived stress, 62.3 (SD= 8.8) for 
anxiety, 57.1 (SD=9.7) for depression, and 51.6 (SD=4.0) for sleep disturbance.  
Aim 1: Perceived Ineffectiveness of Dysmenorrhea Treatments 
Figure 1 and Table 1 shows treatments women used and perceived effectiveness/ 
ineffectiveness for each treatment. The three most common treatments that women tried were 
ibuprofen, acetaminophen, and combined OCP.  
For commonly used pain medications, 29.3% of ibuprofen users rated it as ineffective, 
and 35.6% of naproxen users rated it as ineffective. For acetaminophen alone, 49.9% of users 
rated it ineffective. For acetaminophen combined with caffeine and antihistamine, 34.8% of 
users rated it as ineffective. For acetaminophen combined with antihistamine and diuretic, 
51.7% of users rated it as ineffective. For opioids, 9.2% of users rated them as ineffective.  
Among estrogen-progestin combined contraceptives, 39.3% of OCPs users, 48.4% of 
implant users, and 40% of estrogen and progestin ring users rated the treatment as ineffective. 
For progestin-only contraceptives, 46.8% of hormonal IUD users rated the treatment as 
ineffective, 40.8% of medroxyprogesterone acetate injection (i.e., shot) users rated the 
treatment as ineffective for dysmenorrhea, and 50.0% of progestin-only pill users rated the 
treatment as ineffective. 




As shown in Table 1, perceived treatment ineffectiveness for ibuprofen, acetaminophen 
combined with caffeine and antihistamine, and combined OCP significantly differed across 
dysmenorrhea symptom-based phenotype groups (all p<0.05). Specifically, women in the 
“multiple severe symptoms” phenotype group had the highest rate of perceiving ibuprofen, 
combined OCPs, and acetaminophen combined with caffeine and antihistamine as ineffective. 
Aim 3: Phenotype, Demographic, Clinical, and Psycho-behavioral Correlates of Perceived 
Treatment Ineffectiveness  
Ibuprofen. Table 2 shows the correlates of perceived ineffectiveness of ibuprofen from 
bivariate and multiple logistic regression models. In bivariate models, the likelihood of perceiving 
ibuprofen as ineffective was 117% higher in the “severe localized pain” phenotype than the “mild 
localized pain” phenotype (OR=2.17, 95% CI 1.32-3.59), 128% higher in the “multiple severe 
symptoms” phenotype than the “mild localized pain” phenotype (OR=2.28, 95% CI 1.34-3.85), 
35% higher with every additional comorbid pain condition (OR=1.35, 95% CI 1.18-1.55), and 2% 
higher with every point increase in pain catastrophizing (OR=1.02, 95% CI 1.01-1.04). In the 
best fit multiple logistic regression model for ibuprofen, the odds of perceiving ibuprofen as 
ineffective was 92% higher for the “severe localized pain” phenotype group (OR= 1.92, 95% CI 
1.13-3.25) and 26% higher for each additional chronic pain condition (OR=1.26, 95% CI 1.08-
1.47).  
Acetaminophen. Table 3 shows the correlates of perceived ineffectiveness of 
acetaminophen from bivariate and multiple logistic regression models. In the bivariate models, 
the likelihood of perceiving acetaminophen as ineffective was 83% higher in the “severe 
localized pain” phenotype than the “mild localized pain” phenotype (OR=1.83, 95% CI 1.09-
3.07), 3% higher for each year increase in age (OR=1.03, 95% CI 1.00-1.07), 73% lower among 
Asian users (OR=0.27, 95% CI .09-.83), 21% higher for each additional comorbid pain condition 
(OR=1.21, 95% CI 1.04-1.41), and 1% higher for every one point increase in pain 
catastrophizing (OR=1.01, 95% CI 1.00-1.02). In the best fit multiple logistic regression model 
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for acetaminophen, the odds of perceived ineffectiveness were 72% higher in the “severe 
localized pain” phenotype (OR= 1.72, 95% CI 1.01-2.91) and 21% higher for each additional 
chronic pain condition (OR=1.21, 95% CI 1.03-1.41).  
Combined OCPs. Table 4 shows the correlates of perceived ineffectiveness of 
combined OCPs from bivariate and multiple logistic regression models. In the bivariate models, 
the likelihood of perceiving OCPs as ineffective was 263% higher in the “severe localized pain” 
phenotype compared to the “mild localized pain” phenotype (OR=3.63, 95% CI 1.74-7.55), 22% 
higher with each additional chronic pain condition (OR=1.22, 95% CI 1.02-1.47), and 161% 
higher for individuals with a comorbid gynecological condition compared to those without 
(OR=2.61, 95% CI 1.43-4.78). In the best fit multiple logistic regression model for OCPs, the 
odds of perceived ineffectiveness were 246% higher in the “severe localized pain” phenotype 
(OR= 3.46, 95% CI 1.58-7.57), 156% higher for individuals with a comorbid gynecological 
condition compared to those without (OR=2.56, 95% CI 1.34-4.89), 6% lower for every one 
point increase in anxiety score (OR=0.94, 95% CI 0.89-1.00), and 6% higher for every one point 
increase in depression score (OR=1.06, 95% CI 1.00-1.03). 
 
Discussion 
In this study, we reported the perceived ineffectiveness of common pharmacological 
dysmenorrhea treatments. We tested whether perceived treatment ineffectiveness differed by 
symptom-based phenotypes, and explored phenotypes, demographic, clinical, and psycho-
behavioral correlates of treatment ineffectiveness. Consistent with previous research,15,16, this 
study shows heterogeneity in perceived dysmenorrhea treatment effectiveness. The 
percentages perceiving NSAIDs as ineffective (i.e., 29.3%-35.6%) were higher than the 18% 
reported in a review of clinical trials.35 The higher NSAIDs ineffectiveness rate reported in our 
study may be due to assessing a more heterogeneous sample compared to highly controlled 
clinical trials. For example, we included women who had comorbid gynecological conditions. We 
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also included participants with chronic overlapping pain conditions, as recommended.36 Given 
the heterogeneity in treatment effectiveness, new and precision-based (i.e., tailored) 
dysmenorrhea treatments are needed. To optimize dysmenorrhea treatments, factors 
associated with perceived treatment effectiveness and ineffectiveness need to be further 
investigated. 
This study is the first to compare perceived dysmenorrhea treatment ineffectiveness by 
symptom-based dysmenorrhea phenotypes. As we hypothesized, women in the more severe 
phenotype groups were less likely to perceive commonly used treatments as effective (NSAIDs, 
acetaminophen, and combined OCPs). We found that dysmenorrhea symptom-based 
phenotypes were significant predictors for the perceived ineffectiveness of ibuprofen, 
acetaminophen, and combined OCPs, even after controlling for other demographic, clinical, and 
psycho-behavioral factors. Findings suggest that certain dysmenorrhea symptom-based 
phenotypes may be more challenging to treat or more treatment-resistant. Given that the 
women in the “multiple severe symptoms” phenotype group experienced pain at multiple sites 
and severe gastrointestinal symptoms, it is likely that different, possibly central pain 
mechanisms may be involved, and thus different treatments may be needed. This “multiple 
severe symptoms” phenotype group may have a heightened sensitivity of the central nervous 
system, which would explain why its members are more likely to fail standard treatments.18 If the 
central mechanisms are significantly involved in the “multiple severe symptoms” phenotype, 
treatments targeting central mechanisms (e.g., tricyclic antidepressants, gabapentin, cognitive 
behavioral interventions, and exercises) 37-39 may be promising.  
For demographic correlates, although age and race were significant in bivariate models 
for acetaminophen only, we found no demographic correlates in multiple logistic regression 
models for any of the three treatments. Older women were more likely to perceive 
acetaminophen as ineffective. It is possible that aging increases the chances for more repeated 
menstrual pain episodes that sensitize the nervous system to pain, which makes dysmenorrhea 
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more refractory to treatment. Longer number of years with dysmenorrhea has been associated 
with a more negative impact of dysmenorrhea on the central nervous system.8 Compared to 
Whites, Asians were less likely to report acetaminophen as an ineffective treatment for 
dysmenorrhea. A previous study suggested that Chinese participants had different 
acetaminophen pharmacokinetics from White participants, with Chinese participants absorbing 
acetaminophen more rapidly than White participants.40 The racial differences could also be due 
to psycho-behavioral (e.g., treatment preferences, family influences), social, and cultural factors.  
For clinical correlates, the number of comorbid pain conditions was significant in 
bivariate models for all three treatments. After controlling for other covariates, comorbid pain 
conditions increased the odds of perceiving ibuprofen or acetaminophen as ineffective. In other 
words, with each additional chronic pain condition, women with dysmenorrhea were more likely 
to be refractory to common over-the-counter pain treatments. This may be a consequence of 
central pain regulatory systems disruption.36 Women with dysmenorrhea and comorbid chronic 
pain may require more intensive treatments or new treatments. In this study, women with a 
comorbid gynecological condition were more likely to perceive combined OCPs as ineffective. It 
is possible that certain gynecological conditions contribute to treatment resistance. It is also 
possible that women who do not respond to combined OCPs as a dysmenorrhea treatment 
were more likely to receive a diagnosis of a gynecological condition, such as endometriosis. 
Additional research on these relationships is warranted. 
For psycho-behavioral factors, pain catastrophizing was significant in bivariate models 
for two of the three treatments (ibuprofen and acetaminophen). However, the effect size values 
(i.e., odds ratios) were very small. In addition, pain catastrophizing was not a significant 
predictor in the multiple regression models. Interestingly, for the multiple logistic regression 
model on combined OCPs, higher depression was associated with perceiving combined OCPs 
as ineffective, while higher anxiety was associated with perceiving combined OCPs as effective. 
It is unclear why depression and anxiety had an inverse relationship with the perceived 
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ineffectiveness of OCPs for treating dysmenorrhea. We conducted a post-hoc analysis to check 
the potential interaction effect of depression and anxiety on the perceived ineffectiveness of 
combined OCPs, but it was not significant (p=0.33). When the interaction term was added, 
however, anxiety and depression no longer had an inverse relationship with perceived 
ineffectiveness. For some women with dysmenorrhea, depression may increase somatic 
symptoms, which heightens the risk of developing other chronic pain conditions41 and 
contributes to ineffectiveness of pharmacological treatments. Research (as summarized in a 
review)42 has suggested that individuals with more depressive symptoms were less likely to 
respond to pain treatments. The complex relationship between OCPs and depression43-45 also 
may impact OCPs’ perceived effectiveness/ineffectiveness in dysmenorrhea. To our knowledge, 
little is known about the impact of anxiety on pharmacological pain treatment outcomes. 
Additional research on these relationships is warranted.  
This study had limitations. First, there were small numbers of users for certain 
treatments (e.g., opioids, progestin-only pills, patch, shot). The perceived effectiveness/ 
ineffectiveness data for these treatments need to be interpreted with caution. Second, we did 
not assess other factors that could impact treatment ineffectiveness, including pathological 
factors (e.g., severity of endometriosis), pharmacogenetics, and medication dosing.15 Research 
has suggested that drug dosage was retrospectively recalled by research participants less 
accurately than drug names.46,47 Longitudinal study designs will be required for future research 
on the effect of medication dosing on treatment effectiveness/ineffectiveness. Third, there could 
be recall bias and self-report bias related to survey responses. In addition, participants might 
recall treatment effectiveness in different ways (e.g., some may have considered certain times 
when treatments were effective/ineffective rather than considering the overall 
effectiveness/ineffectiveness of treatments over longer spans of time). Fourth, the cross-
sectional design prevents conclusions about causality. It is possible that certain covariates (e.g., 
symptom-based phenotypes and psycho-behavioral factors) reflect the 
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effectiveness/ineffectiveness of treatments rather than lead to different treatment outcomes. 
Fifth, as we intended to limit the length of our survey, we did not investigate the perceived 
effectiveness/ineffectiveness of non-pharmacological treatments. Previous research suggests 
that women use a large variety of complementary health approaches and non-pharmacological 
strategies (e.g., heat, dietary supplements) for dysmenorrhea.24,48,49 Factors that affect their 
differential effectiveness among women need to be investigated in the future.    
Despite these limitations, there are implications for future research. First, in clinical trials 
evaluating dysmenorrhea treatments, researchers can test if symptom-based dysmenorrhea 
phenotypes are associated with treatment responsiveness. Second, additional research is 
needed to explore factors that may explain heterogeneity in treatment effectiveness. Such 
research is necessary to develop precision-based dysmenorrhea treatments. Third, additional 
research could evaluate whether treatments that target the central nervous system (e.g., 
tricyclic antidepressants and gabapentin) in the “multiple severe symptoms” phenotype group 
are effective. If positive, findings could provide confirmation of central nervous system 
involvement underlying the pain.18  
Conclusion  
A significant percentage of women perceived common pharmacological dysmenorrhea 
treatments as ineffective. Phenotypes, clinical, and psycho-behavioral factors were associated 
with treatment ineffectiveness. Future research should test if symptom-based phenotypes are 
associated with treatment effectiveness in clinical trials and investigate other factors that affect 
treatment effectiveness, so that dysmenorrhea treatments can be tailored to individuals. 
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Figure 1. Perceived Ineffectiveness and Effectiveness of Dysmenorrhea Treatments 
Treatments are ordered based on the frequency of use. 




Acetaminophen, caffeine, and antihistamine combined (n=164)
Naproxen (n=163)





Progestin-only pill  (n=22)
Estrogen and Progestin Ring (n=15)
Skin Patch (n=12)
Not at all Effective % A Little Effective % Moderately Effective % Quite Effective % Extremely Effective %
Table 1. Perceiving Treatment as Ineffective by Dysmenorrhea Symptom-based Phenotypes (n=678) 











Ibuprofen (n=461) 32(19.39%) 57(34.34%) 46(35.38%) 0.0018 
Acetaminophen (n=329) 46(41.44%) 70(56.45%) 48(51.06%) 0.0682 
Combined OCP (n=191) 15(23.44%) 40(52.63%) 20(39.22%) 0.0019 
Acetaminophen, caffeine, and 
antihistamine combined (n=164) 
11(22%) 24(34.29%) 22(50%) 0.0173 
Naproxen (n=163) 11(23.91%) 26(38.81%) 21(42%) 0.1452 
Acetaminophen, antihistamine, 
and diuretic combined (n=89) 
11(47.83%) 17(44.74%) 18(64.29%) 0.2681 
Opioids (n=65) 1(12.5%) 4(13.79%) 1(3.57%) 0.3831 
Hormonal IUD (n=47) 2(16.67%) 11(55%) 9(60%) 0.0632 
Shot (n=49) 3(27.27%) 7(35%) 10(55.56%) 1.0000 
Implant (n=31) 4(57.14%) 8(61.54%) 3(27.27%) 0.2438 
Progestin-only pill (n=22) 3(33.33%) 4(57.14%) 4(66.67%) 0.5624 
Estrogen-Progestin Ring (n=15) 1(25%) 4(50%) 1(33.33%) 0.7986 
Patch (n=12) 1(100%) 5(62.5%) 2(66.67%) 0.5758 
1Treatments are ordered based on the frequency of use. 
2Pvalue is based on comparison between perceived effective and perceived ineffective across three symptom-based 
phenotypes using Fisher’s Exact Test; Bolded: p<.05 
OCP: Oral contraceptive pills. IUD: Intrauterine device.  
Table 2. Correlates of Perceived Treatment Ineffectiveness for Ibuprofen (n=461) 
Bivariate Logistic Regression Multiple Logistic Regression1 
Variable (reference) Beta SE OR 95% CI p Beta SE OR 95% CI p 
Dysmenorrhea Symptom-Based Phenotypes 
Severe Localized Pain (Mild) 0.78 0.26 2.17 [1.32-3.59] 0.00 0.65 0.27 1.92 [1.13-3.25] 0.01 
Severe Multiple Symptoms (Mild) 0.82 0.27 2.28 [1.34-3.85] 0.00 0.51 0.29 1.67 [0.94-2.94] 0.08 
Demographics 
Age  0.03 0.01 1.03 [1.00-1.05] 0.06 
Ethnicity-Hispanic -0.15 0.31 0.86 [0.47-1.59] 0.64 -0.08 0.33 0.92 [0.48-1.76] 0.81 
Race Asian (White) -0.30 0.48 0.74 [0.29-1.91] 0.53 
 Black (White) -0.44 0.34 0.65 [0.34-1.25] 0.20 
       Other (White) 0.30 0.31 1.35 [0.73-2.48] 0.34 
Clinical 
Number of chronic pain conditions 0.30 0.07 1.35 [1.18-1.55] 0.00 0.23 0.08 1.26 [1.08-1.47] 0.00 
Comorbid gynecological condition 0.38 0.22 1.46 [0.95-2.26] 0.09 0.16 0.24 1.17 [0.79-1.88] 0.49 
Psycho-behavioral 
Pain Catastrophizing 0.02 0.01 1.02 [1.01-1.04] 0.01 0.02 0.01 1.02 [1.00-1.04] 0.07 
Perceived Stress  0.00 0.02 1.00 [0.97-1.03] 0.93 -0.04 0.02 0.96 [0.92-1.00] 0.05 
Anxiety  0.02 0.01 1.02 [0.99-1.04] 0.22 
Depression 0.02 0.01 1.02 [1.00-1.04] 0.11 
Sleep disturbance  -0.00 0.03 0.99 [0.95-1.05] 0.98 
SE: Standard errors; OR: Odds Ratio; CI: Confidence Interval; Bolded, p<.05. For both bivariate and multiple logistic models, respondents who perceived ibuprofen as 
effective were the outcome reference group.  
1The covariates for the multiple logistic regression model were selected by fitting all possible combinations of covariate variables and selecting the model with the 
lowest Akaike’s Information Criteria; Pseudo R2: Nagelkerke R2 =0.12, McKelveyZavoina R2=0.09, McFadden R2 =0.07 
Table 3. Correlates of Perceived Treatment Ineffectiveness for Acetaminophen (n=329) 
Bivariate Logistic Regression Multiple Logistic Regression1 
Variable (reference) Beta SE OR 95% CI p Beta SE OR 95% CI p 
Dysmenorrhea Symptom-Based Phenotypes 
Severe Localized Pain (Mild) 0.61 0.26 1.83 0.02 0.54 0.27 1.72 <.05 
Severe Multiple Symptoms (Mild) 0.39 0.28 1.47 0.17 0.30 0.30 1.35 0.32 
Demographics 
Age  0.03 0.02 1.03 0.04 
Ethnicity-Hispanic -0.28 0.34 0.76 0.42 -0.23 0.36 0.79 0.51 
Race Asian (White) -1.33 0.58 0.27 0.02 
 Black (White) -0.23 0.35 0.80 0.51 
       Other (White) 0.11 0.35 1.11 0.77 
Clinical 
Number of chronic pain conditions 0.19 0.08 1.21 0.01 0.19 0.08 1.21 0.03 
Comorbid gynecological condition 0.35 0.24 1.42 0.14 
Psycho-behavioral 0.26 0.25 1.30 0.30 
Pain Catastrophizing  0.01 0.01 1.01 <0.50 
Perceived Stress   0.01 0.02 1.01 0.73 
Anxiety   0.01 0.01 1.01 0.45 
Depression  0.02 0.01 1.02 0.16 
Sleep disturbance  -0.03 0.03 0.97 0.23 
SE: Standard errors; OR: Odds Ratio; CI: Confidence Interval; Bolded, p<.05. For both bivariate and multiple logistic models, respondents who perceived acetaminophen 
as effective were the outcome reference group. 
1The covariates for the multiple logistic regression model were selected by fitting all possible combinations of covariate variables and selecting the model with the 
lowest Akaike’s Information Criteria; Pseudo R2: Nagelkerke R2 =0.10, McKelveyZavoina R2=0.06, McFadden R2 =0.05. 
Table 4 Correlates of Perceived Treatment Ineffectiveness for Combined Oral Contraceptive Pills (n=191) 
Bivariate Logistic Regression Multiple Logistic Regression1 
Variable (reference) Beta SE OR 95% CI p Beta SE OR 95% CI p 
Dysmenorrhea Symptom-Based Phenotypes 
Severe Localized Pain (Mild) 1.29 0.37 3.63 [1.74-7.55] 0.00 1.24 0.40 3.46 [1.58-7.57] 0.00 
Severe Multiple Symptoms (Mild) 0.75 0.41 2.11 [0.94-4.73] 0.07 0.57 0.44 1.77 [0.75-4.19] 0.20 
Demographics 
Age  0.03 0.02 1.03 [0.99-1.07] 0.16 
Ethnicity-Hispanic -0.11 0.50 0.89 [0.33-2.38] 0.82 
Race Asian (White) 1.13 0.88 3.08 [0.55-17.34] 0.20 
 Black (White) -0.17 0.53 0.84 [0.30-2.39] 0.75 
       Other (White) -0.38 0.62 0.69 [0.20-2.32] 0.54 
Clinical 
Number of chronic pain conditions 0.20 0.09 1.22 [1.02-1.47] 0.03 
Comorbid gynecological condition 0.96 0.31 2.61 [1.43-4.78] 0.00 0.94 0.33 2.56 [1.34-4.89] 0.00 
Psycho-behavioral 
Pain Catastrophizing 0.02 0.01 1.02 [1.00-1.05] 0.05 
Perceived Stress  0.01 0.03 1.01 [0.97-1.06] 0.60 
Anxiety  0.01 0.02 1.01 [0.97-1.04] 0.73 -0.06 0.03 0.94 [0.89-1.00] 0.03 
Depression 0.03 0.02 1.04 [1.00-1.07] 0.05 0.06 0.03 1.06 [1.00-1.13] 0.04 
Sleep disturbance  0.01 0.03 1.01 [0.95-1.07] 0.86 
SE: Standard errors; OR: Odds Ratio; CI: Confidence Interval; Bolded, p<.05. For both bivariate and multiple logistic models, respondents who perceived combined oral 
contraceptive pills as effective were the outcome reference group. 
1The covariates for the multiple logistic regression model were selected by fitting all possible combinations of covariate variables and selecting the model with the 
lowest Akaike’s Information Criteria; Pseudo R2: Nagelkerke R2 =0.18, McKelveyZavoina R2=0.17, McFadden R2 =0.11.  
